Lactobacillus rhamnosus GG effectivity compared to basillus claussi
Reading File
Searching PubMed
Lactobacillus rhamnosus GG AND Bacillus clausii comparison
Searching the Web
Lactobacillus rhamnosus GG vs Bacillus clausii clinical effectiveness comparison 2024
Finding Sources
Searching PubMed
"Lactobacillus rhamnosus GG" AND diarrhea AND probiotic
Searching PubMed
"Bacillus clausii" AND probiotic AND diarrhea
Reading Article
Reading Article
Reading Article
Reading File
I now have enough evidence to provide a thorough, well-cited comparison. Here is the full analysis:
Lactobacillus rhamnosus GG (LGG) vs. Bacillus clausii - Effectiveness Comparison
1. Basic Characteristics
| Feature | LGG | Bacillus clausii |
|---|---|---|
| Type | Gram-positive rod (Lactobacillaceae) | Gram-positive spore-forming rod (Bacillaceae) |
| Form | Vegetative bacteria | Spores (highly stable) |
| Acid/antibiotic resistance | Moderate | Excellent - spores survive gastric acid and most antibiotics |
| Common brands | Culturelle, LGG | Enterogermina (O/C, SIN, N/R, T strains) |
| Oxygen requirement | Anaerobic/microaerophilic | Aerobic |
2. Mechanism of Action
LGG:
- Adheres to intestinal epithelium via pili (SpaCBA-SrtC1 pili cluster), competing with pathogens
- Produces antimicrobial substances (bacteriocins, organic acids)
- Enhances tight junction integrity - strengthens the gut barrier
- Stimulates secretory IgA and anti-inflammatory cytokines (IL-10)
- Accelerates immune maturation in children
Bacillus clausii:
- Spores are acid- and antibiotic-resistant, germinating in the small intestine
- Produces antimicrobial substances active against Gram-positive pathogens
- Modulates innate and adaptive immunity via interaction with gut-associated lymphoid tissue (GALT)
- Notably, spores can co-exist with ongoing antibiotic therapy - a significant practical advantage
- 2024 RCT (PMID 38494525) showed improvements in immunological markers (IgA, T-regulatory cells) in persistent diarrhea in children
3. Clinical Evidence by Indication
A. Acute Infectious Diarrhea in Children
LGG has the largest and most consistent evidence base here:
- The 2020 Cochrane systematic review (82 trials, 12,127 participants, PMID 33295643) found that for low-risk-of-bias trials, the overall benefit of probiotics - including LGG - on diarrhea lasting ≥48 hours was non-significant (RR 1.00; moderate certainty). However, earlier pooled analyses across all studies showed shorter diarrhea duration on average.
- ESPGHAN guidelines specifically recommend LGG (alongside Saccharomyces boulardii and L. reuteri DSM 17938) as evidence-based options for acute gastroenteritis management in children.
- Geographically: higher effect sizes seen in European and Asian trials vs. North American studies (likely baseline microbiota differences).
- LGG is most clearly beneficial in rotavirus diarrhea, reducing duration by roughly 1 day (Sherris & Ryan's Medical Microbiology, 8th Ed.).
Bacillus clausii:
- 2018 meta-analysis (6 RCTs, 1,298 patients, PMID 30103531): B. clausii significantly reduced diarrhea duration (MD = -9.12 h, 95% CI: -16.49 to -1.75, p = 0.015) and hospitalization duration (MD = -0.85 days, p = 0.017) vs. control. Good safety profile.
- 2025 meta-analysis of Enterogermina specifically (11 RCTs + 3 non-RCTs, PMID 40381158): duration of diarrhea reduced by 0.60 Hedge's g; stool frequency reduced by 0.34 Hedge's g; hospital stay reduced by 0.27 Hedge's g (all p<0.05). Authors conclude it is effective and well-tolerated but note more head-to-head trials are needed.
Head-to-head (Sharma et al., RCT - Semantic Scholar): In a direct 3-arm RCT comparing LGG, B. clausii, and S. boulardii in children with acute diarrhea, LGG significantly outperformed B. clausii in reducing stool frequency and improving stool consistency, with no adverse effects.
B. Antibiotic-Associated Diarrhea (AAD)
LGG:
- Strong meta-analysis evidence for preventing AAD. The 2021 systematic review (PMID 33844181) supports LGG as one of the top two choices (with S. boulardii) for AAD prevention.
- ESPGHAN recommends LGG and S. boulardii specifically for AAD prevention.
Bacillus clausii:
- Its spore form means it is not killed by concurrent antibiotics - a theoretical advantage.
- Harrison's (22nd Ed., 2025) notes that B. clausii (alongside Lactobacillus spp. and S. boulardii) did not alter H. pylori eradication rates but did decrease antibiotic-associated side effects including nausea, dysgeusia, diarrhea, and abdominal discomfort.
- However, it is not currently guideline-recommended for AAD prevention in the same tier as LGG and S. boulardii.
C. Persistent/Chronic Diarrhea
LGG: Some RCT evidence in persistent diarrhea in Indian children (Basu et al., 2007), but results are mixed.
Bacillus clausii: 2024 RCT (PMID 38494525) showed promising clinical AND immunological efficacy for persistent diarrhea in children, with improved IgA levels and T-regulatory cell counts. This is a newer area where B. clausii may have a specific niche.
D. Other Indications
| Indication | LGG | Bacillus clausii |
|---|---|---|
| IBS | Moderate evidence (pain frequency/intensity) | Limited |
| IBD (Crohn's) | No benefit in maintaining remission (small trials) | Insufficient data |
| H. pylori (adjunct) | Some supportive data | Reduces side effects of therapy (Harrison's) |
| NAFLD in children | Improved ALT (small trials) | Not studied |
| Radiation injury | Radioprotective effect (preclinical + early clinical) | Not studied |
4. Safety
Both probiotics are considered safe with very low rates of adverse effects. There are rare case reports of Lactobacillus bacteremia in severely immunocompromised patients on LGG. B. clausii spores have an excellent safety record across all age groups, including neonates.
5. Summary Verdict
| Parameter | LGG | Bacillus clausii |
|---|---|---|
| Evidence volume | Very high (hundreds of RCTs) | Moderate (growing) |
| Guideline recognition | ESPGHAN, WGO, AAP endorsed | Not yet in top-tier guidelines |
| Acute gastroenteritis | Strong benefit (especially rotavirus) | Moderate, statistically significant benefit |
| AAD prevention | Well-established, guideline-backed | Theoretical advantage (antibiotic-stable); less proven |
| Antibiotic co-administration | Cannot be given at same time (lives bacteria killed) | Can be given simultaneously (spores survive) |
| Acute diarrhea (head-to-head) | Superior to B. clausii in at least one direct RCT | Less effective than LGG in direct comparison |
| Persistent diarrhea | Limited evidence | Promising 2024 RCT data |
| Practical storage | Requires refrigeration (some formulations) | Room temperature stable (spore form) |
Bottom line: LGG has the stronger overall evidence base and is the more guideline-recognized probiotic for acute gastroenteritis and AAD prevention. In direct head-to-head comparison, LGG outperforms B. clausii for acute childhood diarrhea. Bacillus clausii's main practical advantages are its antibiotic resistance (can be co-administered), room-temperature stability, and its emerging role in persistent diarrhea. The 2025 meta-analysis (PMID 40381158) suggests B. clausii Enterogermina is genuinely effective, but the researchers themselves call for more direct comparative trials.
Key references:
- Cochrane Review on probiotics for acute diarrhea: PMID 33295643
- B. clausii meta-analysis 2018: PMID 30103531
- B. clausii (Enterogermina) meta-analysis 2025: PMID 40381158
- B. clausii in persistent diarrhea RCT 2024: PMID 38494525
- Harrison's Principles of Internal Medicine, 22nd Ed. (H. pylori context)
- Sherris & Ryan's Medical Microbiology, 8th Ed. (LGG and rotavirus)
Harrison book chapters
Finding Sources
You've run out of free credits. Sign up for a free account to continue using Orris.
This is a shared conversation. Sign in to Orris to start your own chat.